456 related articles for article (PubMed ID: 26916304)
41. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
Westmark PR; Tanratana P; Sheehan JP
J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
[TBL] [Abstract][Full Text] [Related]
43. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A
Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769
[TBL] [Abstract][Full Text] [Related]
44. Global assays and the management of oral anticoagulation.
Brinkman HJ
Thromb J; 2015; 13():9. PubMed ID: 25762867
[TBL] [Abstract][Full Text] [Related]
45. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
[TBL] [Abstract][Full Text] [Related]
46. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.
Perzborn E; Gruber A; Tinel H; Marzec UM; Buetehorn U; Buchmueller A; Heitmeier S; Laux V
Thromb Haemost; 2013 Jul; 110(1):162-72. PubMed ID: 23636219
[TBL] [Abstract][Full Text] [Related]
47. Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.
Solbeck S; Meyer MA; Johansson PI; Meyer AS; Cotton BA; Stensballe J; Schött U; Ostrowski SR
Int J Cardiol; 2014 Oct; 176(3):794-9. PubMed ID: 25156858
[TBL] [Abstract][Full Text] [Related]
48. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC.
Philippou H; Adami A; Lane DA; MacGregor IR; Tuddenham EG; Lowe GD; Rumley A; Ludlam CA
Thromb Haemost; 1996 Jul; 76(1):23-8. PubMed ID: 8819246
[TBL] [Abstract][Full Text] [Related]
49. Indications and Methods of Anticoagulation Reversal.
Holzmacher JL; Sarani B
Surg Clin North Am; 2017 Dec; 97(6):1291-1305. PubMed ID: 29132510
[TBL] [Abstract][Full Text] [Related]
50. Thrombin generation capacity of prothrombin complex concentrate in an in vitro dilutional model.
Grottke O; Rossaint R; Henskens Y; van Oerle R; Ten Cate H; Spronk HM
PLoS One; 2013; 8(5):e64100. PubMed ID: 23696866
[TBL] [Abstract][Full Text] [Related]
51. Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting.
Ghadimi K; Levy JH; Welsby IJ
Anesth Analg; 2016 May; 122(5):1287-300. PubMed ID: 26983050
[TBL] [Abstract][Full Text] [Related]
52. Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B.
Kim HC; McMillan CW; White GC; Bergman GE; Saidi P
Semin Hematol; 1990 Apr; 27(2 Suppl 2):30-5. PubMed ID: 2094957
[TBL] [Abstract][Full Text] [Related]
53. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
[TBL] [Abstract][Full Text] [Related]
54. Hemostatic assessment of combined anticoagulant therapy using warfarin and prothrombin complex concentrates in a case of severe protein C deficiency.
Ogiwara K; Nogami K; Mizumachi K; Nakagawa T; Noda N; Ohga S; Shima M
Int J Hematol; 2019 Jun; 109(6):650-656. PubMed ID: 30963470
[TBL] [Abstract][Full Text] [Related]
55. Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study.
Dargaud Y; Desmurs-Clavel H; Marin S; Bordet JC; Poplavsky JL; Negrier C
J Thromb Haemost; 2008 Jun; 6(6):962-8. PubMed ID: 18373620
[TBL] [Abstract][Full Text] [Related]
56. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
[TBL] [Abstract][Full Text] [Related]
57. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
[TBL] [Abstract][Full Text] [Related]
58. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
59. Ex vivo reversal of the anticoagulant effects of edoxaban.
Halim AB; Samama MM; Mendell J
Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
[TBL] [Abstract][Full Text] [Related]
60. Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers.
Arellano-Rodrigo E; Lopez-Vilchez I; Galan AM; Molina P; Reverter JC; Carné X; Villalta J; Tassies D; Lozano M; Díaz-Ricart M; Escolar G
Transfus Med Rev; 2015 Oct; 29(4):242-9. PubMed ID: 26364029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
